Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Euronext Alternext  >  NOXXON Pharma NV    ALNOX   NL0012044762

NOXXON PHARMA NV

(ALNOX)
  Report
SummaryQuotesChartsNewsCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsPress ReleasesOfficial PublicationsSector news

NOXXON Pharma N.V.: Half-yearly Report on the Liquidity Contract With Invest Securities

share with twitter share with LinkedIn share with facebook
share via e-mail
0
01/16/2020 | 12:01pm EST

Regulatory News:

NOXXON Pharma N.V. (Paris:ALNOX) (Euronext Growth Paris: ALNOX), a biotechnology company focused on improving cancer treatments by targeting the tumor microenvironment (TME), announced today that pursuant to the liquidity contract entrusted to Invest Securities by NOXXON Pharma N.V. the following assets appeared on the liquidity account:

As of December 31, 2019:

  • Number of shares: 14,540
  • Cash balance of the liquidity account: € 31,119.15

For the period July 1, 2019 – December 31, 2019:

  • Total number of shares bought: 88,63
    representing an amount of: € 41,338.86
    representing total transactions of: 91
  • Total number of shares sold: 107,902
    representing an amount of: € 52,794.92
    representing total transactions of: 91

As a reminder, as of June 30, 2019, the following assets appeared in the liquidity account:

  • Number of shares: 33,809
  • Cash balance of the liquidity account: € 19,663.09

About NOXXON

NOXXON’s oncology-focused pipeline acts on the tumor microenvironment (TME) and the cancer immunity cycle by breaking the tumor protection barrier and blocking tumor repair. By neutralizing chemokines in the tumor microenvironment, NOXXON’s approach works in combination with other forms of treatment to weaken tumor defenses against the immune system and enable greater therapeutic impact. Building on extensive clinical experience and safety data, the lead program NOX-A12 has delivered top-line data from a Keytruda® combination trial in metastatic colorectal and pancreatic cancer patients and further studies are being planned in these indications. In September 2019 the company initiated an additional trial with NOX-A12 in brain cancer in combination with radiotherapy. The combination of NOX-A12 and radiotherapy has been granted orphan drug status in the US and EU for the treatment of certain brain cancers. The company’s second clinical-stage asset NOX-E36 is a Phase 2 TME asset targeting the innate immune system. NOXXON plans to test NOX‑E36 in patients with solid tumors both as a monotherapy and in combination. Further information can be found at: www.noxxon.com

Keytruda® is a registered trademark of Merck Sharp & Dohme Corp

LinkedIn: https://www.linkedin.com/company/noxxon-pharma-ag
Twitter: https://twitter.com/noxxon_pharma

Disclaimer

Certain statements in this communication contain formulations or terms referring to the future or future developments, as well as negations of such formulations or terms, or similar terminology. These are described as forward-looking statements. In addition, all information in this communication regarding planned or future results of business segments, financial indicators, developments of the financial situation or other financial or statistical data contains such forward-looking statements. The company cautions prospective investors not to rely on such forward-looking statements as certain prognoses of actual future events and developments. The company is neither responsible nor liable for updating such information, which only represents the state of affairs on the day of publication.


© Business Wire 2020
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on NOXXON PHARMA NV
01/20NOXXON PHARMA : announces another capital increase of 0.5 million Euro through a..
PU
01/20NOXXON PHARMA : Announces Another Capital Increase of €0.5 Million Through a Pri..
BU
01/20NOXXON PHARMA NV : Admission of new securities
CO
01/17NOXXON PHARMA : N.V. - Half-yearly Report on the Liquidity Contract With Invest ..
AQ
01/16NOXXON PHARMA : Half-yearly report on the liquidity contract with Invest Securit..
PU
01/16NOXXON PHARMA N.V. : Half-yearly Report on the Liquidity Contract With Invest Se..
BU
01/14NOXXON PHARMA : announces a capital increase of 0.5 million Euro through a priva..
PU
01/14NOXXON PHARMA : Announces a Capital Increase of €0.5 Million Through a Private P..
BU
2019NOXXON PHARMA : announces first brain cancer patient reaches 10 weeks of treatme..
AQ
2019NOXXON PHARMA : Announces First Brain Cancer Patient Reaches 10 Weeks of Treatme..
BU
More news
Financials (EUR)
Sales 2019 -
EBIT 2019 -5,05 M
Net income 2019 -5,50 M
Debt 2019 5,06 M
Yield 2019 -
P/E ratio 2019 -
P/E ratio 2020 -
EV / Sales2019 infx
EV / Sales2020 14,5x
Capitalization 7,38 M
Chart NOXXON PHARMA NV
Duration : Period :
NOXXON Pharma NV Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends NOXXON PHARMA NV
Short TermMid-TermLong Term
TrendsNeutralNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 2
Average target price 2,48  €
Last Close Price 0,48  €
Spread / Highest target 431%
Spread / Average Target 416%
Spread / Lowest Target 400%
EPS Revisions
Managers
NameTitle
Aram Andrew Mangasarian Chief Executive Officer
Maurizio PetitBon Chairman-Supervisory Board
Jarl Ulf Birger Jungnelius Chief Medical Officer
Hubert Birner Member-Supervisory Board
Walter Wenninger Member-Supervisory Board
Sector and Competitors
1st jan.Capitalization (M$)
NOXXON PHARMA NV-17.53%8
IQVIA HOLDINGS INC.2.69%30 495
LONZA GROUP11.86%30 215
CELLTRION, INC.--.--%19 914
SEATTLE GENETICS, INC.-1.16%18 926
INCYTE CORPORATION-12.44%16 385